Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Certification | 2 | 2017 | 24 | 0.670 |
Why?
|
| Pancreas Transplantation | 7 | 2021 | 17 | 0.650 |
Why?
|
| General Surgery | 2 | 2017 | 54 | 0.640 |
Why?
|
| Test Taking Skills | 1 | 2017 | 2 | 0.560 |
Why?
|
| Internship and Residency | 2 | 2017 | 211 | 0.530 |
Why?
|
| Clinical Competence | 1 | 2017 | 206 | 0.470 |
Why?
|
| Kidney Transplantation | 4 | 2021 | 119 | 0.400 |
Why?
|
| Arteriovenous Shunt, Surgical | 2 | 2022 | 22 | 0.370 |
Why?
|
| Organ Transplantation | 4 | 2021 | 33 | 0.350 |
Why?
|
| Liver Transplantation | 4 | 2014 | 89 | 0.330 |
Why?
|
| Tissue and Organ Procurement | 4 | 2009 | 37 | 0.260 |
Why?
|
| Educational Measurement | 2 | 2017 | 57 | 0.250 |
Why?
|
| Graft Rejection | 4 | 2009 | 68 | 0.250 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.190 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 12 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 13 | 0.190 |
Why?
|
| Renal Dialysis | 3 | 2022 | 84 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 54 | 0.180 |
Why?
|
| Graft Survival | 6 | 2014 | 97 | 0.180 |
Why?
|
| Surgical Instruments | 1 | 2020 | 25 | 0.180 |
Why?
|
| Adult | 15 | 2020 | 7831 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2020 | 75 | 0.170 |
Why?
|
| Suture Techniques | 1 | 2020 | 157 | 0.160 |
Why?
|
| Humans | 22 | 2022 | 27074 | 0.150 |
Why?
|
| Intestines | 2 | 2008 | 80 | 0.140 |
Why?
|
| Male | 16 | 2020 | 14772 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2022 | 3538 | 0.140 |
Why?
|
| United States | 4 | 2017 | 2035 | 0.140 |
Why?
|
| Female | 15 | 2020 | 15213 | 0.130 |
Why?
|
| Program Evaluation | 1 | 2017 | 120 | 0.130 |
Why?
|
| Treatment Outcome | 10 | 2022 | 3485 | 0.130 |
Why?
|
| Simulation Training | 1 | 2017 | 39 | 0.130 |
Why?
|
| Education, Medical, Graduate | 1 | 2017 | 77 | 0.130 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 132 | 0.130 |
Why?
|
| Curriculum | 1 | 2017 | 138 | 0.130 |
Why?
|
| Quality Improvement | 1 | 2017 | 138 | 0.130 |
Why?
|
| Time Factors | 5 | 2022 | 1433 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 37 | 0.110 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 2 | 0.110 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 14 | 0.110 |
Why?
|
| Middle Aged | 13 | 2020 | 8923 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 13 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 124 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 37 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 82 | 0.100 |
Why?
|
| Vascular Patency | 2 | 2022 | 17 | 0.090 |
Why?
|
| Liver | 2 | 2009 | 145 | 0.090 |
Why?
|
| Transplantation, Homologous | 2 | 2009 | 278 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 120 | 0.090 |
Why?
|
| Child | 6 | 2009 | 1295 | 0.090 |
Why?
|
| Stomach | 1 | 2009 | 14 | 0.080 |
Why?
|
| Vascular Surgical Procedures | 1 | 2009 | 23 | 0.080 |
Why?
|
| Leucine | 1 | 2009 | 10 | 0.080 |
Why?
|
| Diabetic Nephropathies | 1 | 2009 | 17 | 0.080 |
Why?
|
| Gastric Fistula | 1 | 2009 | 5 | 0.080 |
Why?
|
| Intestinal Fistula | 1 | 2009 | 3 | 0.080 |
Why?
|
| Living Donors | 1 | 2009 | 16 | 0.080 |
Why?
|
| Colonic Diseases | 1 | 2009 | 7 | 0.080 |
Why?
|
| Hypoglycemia | 1 | 2009 | 12 | 0.080 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2008 | 4 | 0.080 |
Why?
|
| Organ Preservation Solutions | 1 | 2008 | 1 | 0.080 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2008 | 11 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2008 | 21 | 0.080 |
Why?
|
| Pancreatectomy | 1 | 2008 | 11 | 0.080 |
Why?
|
| Colon | 1 | 2009 | 119 | 0.080 |
Why?
|
| Menorrhagia | 1 | 2008 | 2 | 0.070 |
Why?
|
| Program Development | 1 | 2008 | 51 | 0.070 |
Why?
|
| Aged | 9 | 2020 | 8997 | 0.070 |
Why?
|
| Hysterectomy | 1 | 2008 | 23 | 0.070 |
Why?
|
| Cystic Fibrosis | 1 | 2007 | 9 | 0.070 |
Why?
|
| Lung Transplantation | 1 | 2007 | 13 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2007 | 127 | 0.070 |
Why?
|
| Tissue Donors | 2 | 2021 | 79 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2008 | 185 | 0.060 |
Why?
|
| Adolescent | 5 | 2009 | 2172 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2009 | 175 | 0.060 |
Why?
|
| Pancreatic Neoplasms | 2 | 2002 | 93 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 257 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 1 | 2002 | 10 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2009 | 641 | 0.050 |
Why?
|
| Vascular Diseases | 1 | 2002 | 42 | 0.050 |
Why?
|
| Waiting Lists | 2 | 2014 | 18 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2022 | 19 | 0.050 |
Why?
|
| Glucuronidase | 1 | 2002 | 10 | 0.050 |
Why?
|
| Esophagectomy | 1 | 2002 | 23 | 0.050 |
Why?
|
| Carcinoma | 1 | 2002 | 67 | 0.050 |
Why?
|
| Esophageal Neoplasms | 1 | 2002 | 50 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 22 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 32 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2002 | 137 | 0.040 |
Why?
|
| Cost Savings | 1 | 2020 | 32 | 0.040 |
Why?
|
| Risk Factors | 2 | 2022 | 2302 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 123 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 153 | 0.040 |
Why?
|
| Incidence | 1 | 2021 | 759 | 0.040 |
Why?
|
| Insulin | 2 | 2008 | 89 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2020 | 916 | 0.040 |
Why?
|
| Infant | 2 | 2008 | 564 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2009 | 4777 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 415 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2015 | 145 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 1792 | 0.030 |
Why?
|
| Young Adult | 2 | 2009 | 1994 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 347 | 0.030 |
Why?
|
| Probability | 2 | 2002 | 88 | 0.020 |
Why?
|
| Reoperation | 2 | 2008 | 925 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2013 | 490 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2002 | 363 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1144 | 0.020 |
Why?
|
| Anastomosis, Surgical | 1 | 2009 | 29 | 0.020 |
Why?
|
| Prognosis | 2 | 2002 | 785 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2009 | 13 | 0.020 |
Why?
|
| Fluoroscopy | 1 | 2009 | 48 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 161 | 0.020 |
Why?
|
| Raffinose | 1 | 2008 | 1 | 0.020 |
Why?
|
| Allopurinol | 1 | 2008 | 3 | 0.020 |
Why?
|
| Procaine | 1 | 2008 | 2 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2008 | 5 | 0.020 |
Why?
|
| Hypersensitivity | 1 | 2009 | 47 | 0.020 |
Why?
|
| Amylases | 1 | 2008 | 5 | 0.020 |
Why?
|
| Glutathione | 1 | 2008 | 22 | 0.020 |
Why?
|
| Mannitol | 1 | 2008 | 11 | 0.020 |
Why?
|
| Lipase | 1 | 2008 | 4 | 0.020 |
Why?
|
| Adenosine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Indiana | 1 | 2008 | 15 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 30 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 104 | 0.020 |
Why?
|
| Rituximab | 1 | 2008 | 48 | 0.020 |
Why?
|
| Pneumoperitoneum, Artificial | 1 | 2008 | 2 | 0.020 |
Why?
|
| Glucose | 1 | 2008 | 49 | 0.020 |
Why?
|
| Fallopian Tubes | 1 | 2008 | 9 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 37 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2008 | 26 | 0.020 |
Why?
|
| Ureter | 1 | 2008 | 29 | 0.020 |
Why?
|
| Cadaver | 1 | 2009 | 375 | 0.020 |
Why?
|
| Biopsy | 1 | 2008 | 201 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 177 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 676 | 0.020 |
Why?
|
| Endoscopy | 1 | 2008 | 179 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2009 | 624 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2009 | 879 | 0.020 |
Why?
|
| Pancreatitis | 1 | 2002 | 21 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 33 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2002 | 21 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2002 | 49 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 47 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2002 | 94 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2002 | 94 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 260 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 199 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 329 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 342 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2002 | 474 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 482 | 0.010 |
Why?
|